GlassScriptPhysician profile
Stacey M Miller
NPI 1124208442
$9,692.18
in general payments reported to CMS, 2019-2025
46 companies · $2,475 in 2025
The $2,475 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $707 · 2020: $345 · 2021: $675 · 2022: $1,618 · 2023: $1,791 · 2024: $2,080 · 2025: $2,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,341 · Education: $6.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,340.63 |
| Education | $6.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $941.09 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $872.02 | 2020-2025 | Ofev, Jascayd |
| Ethicon INC. | $754.53 | 2021-2023 | Monarch Platform |
| Astrazeneca Pharmaceuticals LP | $720.81 | 2019-2025 | Airsupra, Breztri, Brilinta |
| Regeneron Healthcare Solutions, INC. | $707.27 | 2022-2025 | Dupixent |
| Genzyme Corporation | $573.91 | 2021-2025 | |
| Harmony Biosciences LLC | $505.93 | 2021-2025 | Wakix |
| Mylan Specialty L.P. | $483.89 | 2022-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $480.69 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Insmed, INC. | $404.52 | 2021-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $294.79 | 2022-2025 | Acthar |
| Viatris Specialty LLC | $290.96 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $240.40 | 2020-2025 | Glassia |
| Amgen INC. | $239.22 | 2019-2020 | |
| Abiomed | $237.33 | 2023-2025 | Impella |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $209.29 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $167.26 | 2019-2025 | Zerbaxa, Keytruda |
| Grifols USA, LLC | $161.47 | 2019-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $149.06 | 2022-2025 | |
| Intuitive Surgical, INC. | $144.14 | 2025 | |
| Verona Pharma, INC. | $138.91 | 2025 | Ohtuvayre |
| Baxter Healthcare | $121.28 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Janssen Pharmaceuticals, INC | $103.76 | 2019-2021 | |
| Shire North American Group INC | $64.51 | 2019 | |
| Amarin Pharma, INC. | $59.78 | 2019-2020 | |
| Lundbeck LLC | $58.29 | 2019-2020 | |
| Pfizer INC. | $51.90 | 2022-2024 | |
| Ani Pharmaceuticals, INC. | $49.58 | 2023-2025 | Purified Cortrophin Gel |
| Electromed, INC. | $43.29 | 2024 | Smartvest |
| United Therapeutics Corporation | $41.86 | 2019-2023 | Tyvaso |
| Inspire Medical Systems, INC. | $36.59 | 2025 | Inspire |
| Astellas Pharma US INC | $35.12 | 2019 | |
| Irhythm Technologies, INC. | $34.95 | 2019 | |
| Pulmonx Corporation | $34.78 | 2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Boston Scientific Corporation | $31.12 | 2024 | |
| Csl Behring | $26.23 | 2023 | Kcentra |
| Bioxcel Therapeutics, INC. | $21.63 | 2023 | Igalmi |
| Teva Pharmaceuticals USA, INC. | $21.28 | 2020 | |
| Genentech USA, INC. | $20.92 | 2023 | Xolair |
| Ambu INC. | $20.19 | 2022 | |
| Philips North America LLC | $18.85 | 2024 | (Ak6) Vest Therapy |
| Abbvie INC. | $17.55 | 2024 | |
| Chiesi USA, INC. | $16.58 | 2022 | |
| Nevro Corp. | $15.05 | 2024 | Senza |
| Sanofi-Aventis U.S. LLC | $14.93 | 2020 | |
| Medtronic, INC. | $14.67 | 2024 | Arcpoint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.